Pacira BioSciences, Inc. (PCRX)
| Market Cap | 917.20M -26.3% |
| Revenue (ttm) | 734.86M +4.6% |
| Net Income | 5.14M |
| EPS | 0.12 |
| Shares Out | 39.35M |
| PE Ratio | 196.81 |
| Forward PE | 7.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,053 |
| Open | 23.64 |
| Previous Close | 23.53 |
| Day's Range | 23.11 - 23.94 |
| 52-Week Range | 18.80 - 27.64 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 29.40 (+26.13%) |
| Earnings Date | Apr 30, 2026 |
About PCRX
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price target is $29.4, which is an increase of 26.13% from the latest price.
News
Doma Perpetual urges Pacira shareholders to vote for its board candidates
DOMA Perpetual Capital Management, which, together with its affiliates, beneficially owns approximately 7.5% of the outstanding shares of common stock of Pacira (PCRX) BioSciences, has sent a letter t...
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates
DOMA Perpetual Believes the Board and Management are Committing Gross Negligence by Misleading Investors About the True Risks the Business Faces; DOMA Contends This Conduct Constitutes a Failure of th...
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the live...
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
Highlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Pr...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patie...
Pacira BioSciences Mails Letter to Stockholders
Details Success of Pacira's 5x30 Strategy and Solid First Quarter 2026 Results Reiterates Board's Unanimous Recommendation that Stockholders Vote “FOR” the Election of Pacira's Highly Qualified Nomin...
PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada
SASKATOON, Saskatchewan, May 01, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform for pharmacist-led...
Pacira price target raised to $32 from $30 at Needham
Needham raised the firm’s price target on Pacira (PCRX) to $32 from $30 and keeps a Buy rating on the shares after its Q1 earnings beat. The company’s Q1 volume…
Pacira BioSciences Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong revenue and volume growth across all major products, supported by expanding reimbursement, strategic partnerships, and robust pipeline progress. Guidance for 2026 was reiterated, with disciplined capital allocation and continued share repurchases.
Pacira reports Q1 EPS 60c, consensus 56c
Reports Q1 revenue $177.4M, consensus $173.34M. “Pacira (PCRX) entered 2026 with strong momentum as our 5×30 strategy continues to generate clear and measurable results,” said Frank D. Lee, chief exec...
Pacira BioSciences Reports First Quarter 2026 Financial Results
-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed en...
PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update
SASKATOON, Saskatchewan, April 30, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for pharmacist-le...
PharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial Results
SASKATOON, Saskatchewan, April 29, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for pharmacist-le...
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
Urges Stockholders to Vote “FOR” Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs -- -- Findings show significant reductions in opioid consumption, healthcare res...
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the li...
Pacira BioSciences Transcript: 25th Annual Needham Virtual Healthcare Conference
The conference highlighted strong 2025 financials, robust growth in EXPAREL, and the strategic 5x30 plan targeting five pillars by 2030. Key pipeline milestones, expanded partnerships, and improved reimbursement are expected to drive future growth and market leadership.
Pacira real-world data clearer in hip arthroplasty, says H.C. Wainwright
H.C. Wainwright says the real-world data on Exparel indicate it can lead to lower or comparable total healthcare costs and reduced opioid usage. Pacira (PCRX) presented real-world data supporting the…
Pacira presents data showing lower healthcare costs for Exparel
Pacira (PCRX) BioSciences presented data from three real-world studies supporting the economic value of Exparel in total hip arthroplasty and total knee arthroplasty procedures performed in hospital o...
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
-- Select findings demonstrate that the use of EXPAREL ® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lo...
Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the li...
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWI...
Pacira price target lowered to $25 from $27 at Barclays
Barclays lowered the firm’s price target on Pacira (PCRX) to $25 from $27 and keeps an Equal Weight rating on the shares. The firm left the company’s Q4 report “encouraged”…
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Years [i] ; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30% [ii] ; The Company's Underperf...
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
-- Issues Statement in Response to DOMA's Nomination of Director Candidates -- -- No Shareholder Action Required at This Time --